|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven hundred three (n = 703) prostate cancer (PCa) patients with confirmed PSA failure after radical therapy were enrolled.
|
31492993 |
2020 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer (PCa) treatment monitoring usually relies on prostate-specific antigen to detect disease progression or relapse.
|
31693605 |
2020 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main drawback of <sup>11</sup>C-choline PET/CT for restaging prostate cancer (PCa) patients with biochemical failure is the relatively low positive detection rate for prostate specific antigen (PSA) < 1 ng/ml.
|
30631911 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate changes in clinical data and pathological features of prostatectomy specimens of prostate cancer (PCa) patients in a large tertiary care center over the last 12 years as potential consequence of reduced acceptance of prostate-specific antigen (PSA)-based screening and implementation of active surveillance as a therapeutic option in PCa.
|
30225798 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant differences in AUCs for IL-35 and prostate-specific antigen were observed with regard to the presence of lymph node and distant metastases in patients with PCA.
|
31186721 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, serum XPNPEP2 levels when combined with PSA levels may result in increased sensitivity for predicting LN metastasis in Pca patients, especially for patients with low serum PSA levels.
|
31296901 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the popularity of serum prostate-specific antigen (PSA) screening, the number of newly diagnosed prostate cancer (PCa) patients is increasing.
|
31251827 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary aim of this retrospective, single-centre analysis was to assess the performance of <sup>68</sup>Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA failure after radical prostatectomy (RP).
|
29905907 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
From November 2014 to March 2018, preoperative TT and PSA were measured in 601 consecutive patients who were not under androgen deprivation and undergoing surgery for PCA.
|
31163438 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher PVI and PCI predicted decreased PCA risk in patients presenting with normal DRE, and a PSA ≤10ng/mL at baseline random biopsy.
|
31466070 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Within five to ten years after radical prostatectomy (RP), approximately 15-34% of prostate cancer (PCa) patients experience biochemical recurrence (BCR), which is defined as recurrence of serum levels of prostate-specific antigen >0.2 µg/L, indicating probable cancer recurrence.
|
31640261 |
2019 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level at diagnosis and the Gleason Score (GS) in prostate biopsy.
|
29523813 |
2018 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though a number of diagnostic tests have been developed to improve on PSA testing, there remains a need for a more informative non-invasive test for PCA.
|
29988684 |
2018 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer (PCa) patients with prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) are at increased risk of mortality, although the natural history of these men is heterogeneous and the optimal management has not been established.
|
28622831 |
2017 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The detection rate of PCA was 49%.The dichotomized PVI >1 stratified PCA risk (odds ratio [OR] 0.455; p<0.0001) beyond age (OR 1.062; p<0.0001), PSA (OR 1.167; p<0.0001), PV (OR 0.957; p<0.0001), and abnormal digital rectal examination (OR 2.094; p<0.0001).
|
28291903 |
2017 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We quantified serum levels of neopterin and tryptophan breakdown (tryptophan, kynurenine, and kynurenine-to-tryptophan ratio) in addition to prostate-specific antigen (PSA) in newly diagnosed prostate cancer (PCa) patients (n = 100) before radical prostatectomy (RP) as well as at time of biochemical recurrence (BCR) after RP (n = 50) in comparison to healthy men (n = 49).
|
28107600 |
2017 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease.
|
22559196 |
2012 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 183 Caucasian men with at least one follow-up visit, PCA was more than doubled in men carrying CT/TT vs CC genotypes (hazard ratio = 2.55, 95% CI = 1.14-5.70) after controlling for age and PSA.
|
20735386 |
2011 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although neither HO-1 overexpression nor PTEN deletions alone in localized PCA showed a statistically significant association with PSA relapse, the combined status of both markers correlated with disease progression (log-rank test, p = 0.01).
|
21381033 |
2011 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Follow-on pathological and functional assessment confirmed cyclin D1 and SPP1 as key mediators of these biological processes, which together with PTEN and SMAD4, form a four-gene signature that is prognostic of prostate-specific antigen (PSA) biochemical recurrence and lethal metastasis in human PCA.
|
21289624 |
2011 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The population consisted of 426 men (205 controls and 221 cases) who underwent prostate-specific antigen screening as part of a PCA early detection program in Tyrol, Austria.
|
20056642 |
2010 |
|
Familial lichen amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed the predictive value of TP53 mutations and prostate-specific antigen (PSA) for tumor progression in prostate cancer (PCa) patients.
|
20592345 |
2010 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we noted that the MIF -173*C variant allele was related to higher clinical stages and PSA values in PCa patients (adjusted OR = 15.68, 95% CI: 7.40-33.23; adjusted OR = 4.37, 95% CI: 2.41-7.92, respectively).
|
19475570 |
2009 |
|
Familial lichen amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSA levels were significantly different between the PCA and BPH groups, 252.37 +/- 308.33 ng/ml vs. 3.5 +/- 2.14 ng/ml (p = 0.001), respectively.
|
18752058 |
2009 |
|
Familial lichen amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) test is an established diagnostic tool for PCA detection, but confirmation of diagnosis by histopathological evaluation of prostate needle biopsies is performed.
|
18384941 |
2008 |